TP53 and diffuse large B-cell lymphoma: Multiple reports have shown disruption of TP53 is involved in lymphomagenesis and treatment resistance, and increased upon relapse in diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies20–22.